JP2022516515A5 - - Google Patents

Info

Publication number
JP2022516515A5
JP2022516515A5 JP2021538230A JP2021538230A JP2022516515A5 JP 2022516515 A5 JP2022516515 A5 JP 2022516515A5 JP 2021538230 A JP2021538230 A JP 2021538230A JP 2021538230 A JP2021538230 A JP 2021538230A JP 2022516515 A5 JP2022516515 A5 JP 2022516515A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
nucleotide sequence
sequence described
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/069048 external-priority patent/WO2020142479A1/en
Publication of JP2022516515A publication Critical patent/JP2022516515A/ja
Publication of JP2022516515A5 publication Critical patent/JP2022516515A5/ja
Priority to JP2024219757A priority Critical patent/JP2025032342A/ja
Pending legal-status Critical Current

Links

JP2021538230A 2018-12-31 2019-12-31 Rna標的化crispr-cas13bを使用するdux4 rna発現停止 Pending JP2022516515A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024219757A JP2025032342A (ja) 2018-12-31 2024-12-16 Rna標的化crispr-cas13bを使用するdux4 rna発現停止

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862786670P 2018-12-31 2018-12-31
US62/786,670 2018-12-31
PCT/US2019/069048 WO2020142479A1 (en) 2018-12-31 2019-12-31 Dux4 rna silencing using rna targeting crispr-cas13b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024219757A Division JP2025032342A (ja) 2018-12-31 2024-12-16 Rna標的化crispr-cas13bを使用するdux4 rna発現停止

Publications (2)

Publication Number Publication Date
JP2022516515A JP2022516515A (ja) 2022-02-28
JP2022516515A5 true JP2022516515A5 (cg-RX-API-DMAC7.html) 2023-01-05

Family

ID=69376003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538230A Pending JP2022516515A (ja) 2018-12-31 2019-12-31 Rna標的化crispr-cas13bを使用するdux4 rna発現停止
JP2024219757A Pending JP2025032342A (ja) 2018-12-31 2024-12-16 Rna標的化crispr-cas13bを使用するdux4 rna発現停止

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024219757A Pending JP2025032342A (ja) 2018-12-31 2024-12-16 Rna標的化crispr-cas13bを使用するdux4 rna発現停止

Country Status (8)

Country Link
US (1) US12545909B2 (cg-RX-API-DMAC7.html)
EP (1) EP3906308A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022516515A (cg-RX-API-DMAC7.html)
KR (1) KR102991281B1 (cg-RX-API-DMAC7.html)
AU (1) AU2019419494B2 (cg-RX-API-DMAC7.html)
CA (1) CA3124963A1 (cg-RX-API-DMAC7.html)
IL (1) IL284447B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020142479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
WO2021142267A1 (en) 2020-01-08 2021-07-15 Scarpmap Llc Methods and computing system for processing ultrasound image to determine health of subdermal tissue
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
AU2021342155A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
CA3203585A1 (en) * 2020-11-30 2022-06-02 Research Institute At Nationwide Children's Hospital Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
CA3220338A1 (en) * 2021-05-25 2022-12-01 Yiannis SAVVA Engineered guide rnas and polynucleotides
JP2024523394A (ja) * 2021-06-17 2024-06-28 エピクリスパー バイオテクノロジーズ, インコーポレイテッド 異常な遺伝子発現を調節するためのシステムおよび方法
TW202317768A (zh) * 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣
EP4401792A4 (en) 2021-09-16 2025-12-03 Avidity Biosciences Inc COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
WO2025137547A1 (en) * 2023-12-22 2025-06-26 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
DE69433922T2 (de) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
USH2191H1 (en) * 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2606152B2 (en) * 2010-08-18 2025-03-12 Fred Hutchinson Cancer Center Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
CA2826273C (en) * 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CA2842798C (en) 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
US10538763B2 (en) 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
CN116814590A (zh) * 2015-10-22 2023-09-29 布罗德研究所有限公司 Vi-b型crispr酶和系统
WO2017073619A1 (ja) 2015-10-26 2017-05-04 国立大学法人東京大学 悪性リンパ腫又は白血病の罹患の有無の判別方法並びに白血病の治療及び/又は予防のための薬剤
TN2018000163A1 (en) * 2015-11-12 2019-10-04 Res Inst Nationwide Childrens Hospital Methods of treating muscular dystrophy
JP6966463B2 (ja) * 2016-02-26 2021-11-17 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法
BR112018070249A2 (pt) * 2016-04-02 2019-01-29 Research Institute At Nationwide Children's Hospital sistema promotor de u6 modificada para expressão específica de tecido
EP3515506B1 (en) * 2016-09-23 2023-09-13 University of Massachusetts Silencing of dux4 by recombinant gene editing complexes
US11160823B2 (en) * 2016-11-07 2021-11-02 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
CN110959039B (zh) 2017-03-15 2025-03-14 博德研究所 新型cas13b直向同源物crispr酶和系统
AU2018251801B2 (en) 2017-04-12 2024-11-07 Massachusetts Institute Of Technology Novel type VI CRISPR orthologs and systems
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment
CA3203585A1 (en) * 2020-11-30 2022-06-02 Research Institute At Nationwide Children's Hospital Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
US20240093191A1 (en) * 2021-02-03 2024-03-21 Research Institute At Nationwide Children's Hospital Compositions and methods for treating disease associated with dux4 overexpression

Similar Documents

Publication Publication Date Title
JP2021534755A5 (cg-RX-API-DMAC7.html)
JP2023527354A5 (cg-RX-API-DMAC7.html)
JP2023504314A5 (cg-RX-API-DMAC7.html)
IL320714A (en) Gene therapy for limb-girdle muscular dystrophy type 2c
JP2022500066A5 (cg-RX-API-DMAC7.html)
CA2562788A1 (en) Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
IL320791A (en) Muscle-specific delivery of microdystrophin using an adeno-associated virus vector for the treatment of muscular dystrophy
JP2023002555A5 (cg-RX-API-DMAC7.html)
JP2023553005A5 (cg-RX-API-DMAC7.html)
JP2020019772A5 (cg-RX-API-DMAC7.html)
JP2021502060A5 (cg-RX-API-DMAC7.html)
JP2021500049A5 (cg-RX-API-DMAC7.html)
JP2021522842A5 (cg-RX-API-DMAC7.html)
IL314884A (en) Methods and materials for galgt2 gene therapy
JP2019513779A5 (cg-RX-API-DMAC7.html)
JP2021528983A5 (cg-RX-API-DMAC7.html)
JP2023533417A5 (cg-RX-API-DMAC7.html)
JP2025032342A (ja) Rna標的化crispr-cas13bを使用するdux4 rna発現停止
Ding et al. Biochemical characterization of Junonia coenia densovirus nonstructural protein NS-1
JP2021522836A5 (cg-RX-API-DMAC7.html)
JP2023551279A5 (cg-RX-API-DMAC7.html)
ATE452983T1 (de) Aav-helferplasmide zur helfervirus-freien verpackung und pseudotypisierung von aav-vektoren
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
JP2021534794A5 (cg-RX-API-DMAC7.html)
FI3373980T3 (fi) Menetelmiä lihasdystrofian hoitamiseksi